The Food and Drug Administration (FDA) has delayed its review of alogliptin, a drug intended to help control type 2 diabetes and manufactured by Takeda Pharmaceutical; Takeda also makes Actos, the controversial diabetes medication linked bladder cancer.
In fact, the FDA’s review, which has been moved to April 2012, is also to include an evaluation of a fixed-dose combination of alogliptin and Actos. In August, the FDA required Takeda to issue a new warning with Actos stating that patients who use the drug for longer than 12 months face an increased risk for developing bladder cancer.
Meanwhile, the Mobile, Alabama, defective drug attorneys at Long & Long continue to actively investigate claims from diabetics who suffer from bladder cancer after having taken Actos to stabilize blood-sugar levels.
Alogliptin is designed to regulate hormones that play a role in blood-glucose levels and is touted by the drug maker as being complementary to pioglitazone, the generic name for Actos.
The sale of Actos has been suspended in some countries, including France and Germany, and the FDA has warned American physicians against prescribing the drug to bladder cancer patients or those with a family history of bladder cancer. Type 2 diabetes is the most common form of the disease, and millions of Americans have been prescribed Actos since its approval by the FDA in 1999.
If you developed bladder cancer after taking Actos in the treatment of type 2 diabetes, please contact the Mobile, Alabama, product liability attorneys at Long & Long, P.C., for your free case evaluation.